Table of Contents Table of Contents
Previous Page  330 / 879 Next Page
Information
Show Menu
Previous Page 330 / 879 Next Page
Page Background

Conclusion: Demonstrated PROS for MDMs

1.

Decreases waiting time to treatment

for H&N, pancreas, anus-

rectal and gynecological cancers

2.

Improves diagnostic/therapeutic paths and ensure application of

guidelines: yes for prostate, breast and glioma

3.

Changes treatments attitude and rate of intervention:

yes for

lung, breast and prostate

4.

Garantees/facilitates timely access to physical/phycho-emotional

rehabilitation programs: yes for prostate and breast

5. Helps and improves management of disease recurrence and timely

access to support and palliative care

6.

Helps enrollement in innovative and experimental therapies: yes for

colo-rectal cancers, breast and prostate

7. Improves the education of professionals involved in patients care

8.

Increases patients satisfaction: yes for prostate and breast

9.

Improves survival:

yes for lung, oesophageal, ovarian and HR

prostate cancers

10. Guarantees a minor risk of law suits

FM Boyle et al: J Clin Oncol 2005, A Fleissig et al Lancet Oncol 2006, MA Sidhom et al

Lancet Oncol 2006, CS Sternberg et al BJU int 2007, LE Horvath et al Lancet Oncol

2010, J Walsh et al BMC Heakth Serv Res 2010, EM Kesson et al BMJ 2012